TrialDiabetes, obesity & metabolism2020

The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.

Lawrence A Leiter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.